Top Markets
#1 iExec RLC iExec RLC +24.11%
#2 API3 API3 +21.64%
#3 Bedrock Bedrock +20.73%
#4 CyberDEX CyberDEX +19.33%
#5 Radicle Radicle +18.96%
#6 Talus Network Talus Network +18.08%
#7 The Bitcoin Bull The Bitcoin Bull +16.86%
#8 Orca Orca +13.08%
#9 VeThor VeThor +12.76%
#10 Nockchain Nockchain +11.65%
Coin of the day
iExec RLC iExec RLC
Settings
Language
ENGLISH
Currency
USD
Theme
Cell Source, Inc. Cell Source, Inc.

Cell Source, Inc.

CLCS
Rank in Stocks #28207
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based... Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Share Price
$0.4
Last synced: 2026-10-02
Market Cap
$27.18M
Change (1 day)
-14.88%
Change (1 year)
8.11%
Country
US
Trade Cell Source, Inc. (CLCS)

Category

Healthcare
P/E ratio for Cell Source, Inc. (CLCS)
P/E ratio as of 2026 TTM: 0
According to Cell Source, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Cell Source, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 30.19 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -24.13 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.44 -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 34.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.